SomaGenics

The company aims to develop a DNA version of its platform for preparing small RNA and RNA fragment sequencing libraries.

The funding will be used to further develop the firm's library construction approach and broaden utility for its small-RNA sequencing platform.

The license covers SomaGenics' RealSeq-AC technology, which is designed to reduce library preparation bias in order to improve small RNA quantification.

The company will use the grant money to develop its resQ-RNA method, which is applicable to FFPE or degraded forensic samples.

The technology involves targeted sequencing of rare extracellular microRNAs ordinarily represented by low numbers of reads and therefore hard to detect.

In an bid to tap a growing interest in using microRNAs as biomarkers of disease or tissue injury, Somagenics has developed a platform, called miR-Direct, for detecting the small, non-coding RNAs in circulation.

Despite encouraging preclinical safety and efficacy data for its RNAi-based hepatitis C treatment, Somagenics has decided to step back from its previous plan to push the agent into phase I testing this year as it waits to see how more advanced small-molecule therapies fare in lat

Researchers from SomaGenics plan to use a $300,000 grant from the National Cancer Institute to develop a method they call mRNA Fragment Quantification, or mR-FQ, which they believe can overcome issues that standard RT-qPCR methods have with fragmented mRNA extracted from formalin

Tekmira Pharmaceuticals this week announced that, along with collaborators at SomaGenics and Roche, it has shown in vivo efficacy of an RNAi molecule against hepatitis C virus.

Pages

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.